Skip to main content
Erschienen in: Immunologic Research 1/2014

01.10.2014

An analysis and decision tool to measure cost benefit of newborn screening for severe combined immunodeficiency (SCID) and related T-cell lymphopenia

verfasst von: Vicki Modell, Megan Knaus, Fred Modell

Erschienen in: Immunologic Research | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Severe combined immunodeficiency (SCID) is a group of syndromes resulting from genetic defects causing absence in T-cell and B-cell function, leading to serious and life-threatening infections. SCID is often fatal in the first 2 years of life if not identified and properly treated. While additional laboratory methods are being developed, the current T-cell receptor excision circle assay has proven to have outstanding specificity and sensitivity to accurately identify infants with SCID and other T-cell lymphopenia. The Jeffrey Modell Foundation (JMF) has a long history of advocacy and continues to promote newborn screening for SCID to be implemented in the United States and worldwide. Based on reports provided by California, New York, Texas, and Wisconsin on the results of their population based newborn screening programs, the overall incidence of SCID averaged 1:33,000 and T-cell lymphopenia averaged 1:6,600. JMF has developed a working algorithm or “decision tree”, validated by peer-reviewed scientific literature, to be used by Public Health Departments and Health Ministries in states, countries, and regions throughout the world. This decision tool allows for local or regional data to be applied to measure the threshold and economic impact of implementing newborn screening for SCID and T-cell lymphopenia.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Buckley RH, Schiff SE, Schif RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 1999;340(7):508–16.CrossRefPubMed Buckley RH, Schiff SE, Schif RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 1999;340(7):508–16.CrossRefPubMed
2.
Zurück zum Zitat Buckley RH. Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes. Immunol Res. 2011;49:25–43.PubMedCentralCrossRefPubMed Buckley RH. Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes. Immunol Res. 2011;49:25–43.PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Myers LA, Patel DD, Puck JM, Buckley RH. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood. 2002;99:872–8.CrossRefPubMed Myers LA, Patel DD, Puck JM, Buckley RH. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood. 2002;99:872–8.CrossRefPubMed
4.
Zurück zum Zitat Patel NC, et al. Outcomes of severe combined immunodeficiency patients treated with hematopoietic stem cell transplantation with and without pre-conditioning. J Allergy Clin Immunol. 2009;124(5):1062-9.e1–4.CrossRef Patel NC, et al. Outcomes of severe combined immunodeficiency patients treated with hematopoietic stem cell transplantation with and without pre-conditioning. J Allergy Clin Immunol. 2009;124(5):1062-9.e1–4.CrossRef
5.
Zurück zum Zitat Puck JM. Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor exision circles. In: Boyce JA, Finkelman F, Shearer WT, Vercelli D, editors. J Allergy Clin Immunol. 2012;129:607–16. Puck JM. Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor exision circles. In: Boyce JA, Finkelman F, Shearer WT, Vercelli D, editors. J Allergy Clin Immunol. 2012;129:607–16.
7.
Zurück zum Zitat Baker M. Universal newborn screening for severe combined immunodeficiency (SCID). [PowerPoint]. Atlanta, GA: APHL CDC Newborn Screening Molecular Workshop; 2012. Baker M. Universal newborn screening for severe combined immunodeficiency (SCID). [PowerPoint]. Atlanta, GA: APHL CDC Newborn Screening Molecular Workshop; 2012.
8.
Zurück zum Zitat Routes JM, Grossman WJ, Verbsky J, Laessig RH, Hoffman GL, Brokopp CD, Baker MW. Statewide newborn screening for severe T-cell lymphopenia. JAMA. 2009;302(22):2465–70.CrossRefPubMed Routes JM, Grossman WJ, Verbsky J, Laessig RH, Hoffman GL, Brokopp CD, Baker MW. Statewide newborn screening for severe T-cell lymphopenia. JAMA. 2009;302(22):2465–70.CrossRefPubMed
9.
Zurück zum Zitat Sebelius, K. (2010, May 21). Letter to the committee chairperson for the Secretary’s advisory committee on heritable disorders in newborns and children US Department of Health and Human Services. http://tinyurl.com/l9baeng. Sebelius, K. (2010, May 21). Letter to the committee chairperson for the Secretary’s advisory committee on heritable disorders in newborns and children US Department of Health and Human Services. http://​tinyurl.​com/​l9baeng.
11.
Zurück zum Zitat Chan K, Davis J, Pai SY, Bonilla FA, Puck JM, Apkon M. A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID). Mol Genet Metab. 2011;104(3):383–9.PubMedCentralCrossRefPubMed Chan K, Davis J, Pai SY, Bonilla FA, Puck JM, Apkon M. A Markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID). Mol Genet Metab. 2011;104(3):383–9.PubMedCentralCrossRefPubMed
13.
Zurück zum Zitat Kwan A, Church JA, Cowan MJ, Agarwal R, Kapoor N, Kohn DB, Lewis DB, McGhee SA, Moore TB, Stiehm ER, Porteus M, Aznar CP, Currier R, Lorey F, Puck JM. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years. J Allergy Clin Immunol. 2013;132(1):140–50. Kwan A, Church JA, Cowan MJ, Agarwal R, Kapoor N, Kohn DB, Lewis DB, McGhee SA, Moore TB, Stiehm ER, Porteus M, Aznar CP, Currier R, Lorey F, Puck JM. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years. J Allergy Clin Immunol. 2013;132(1):140–50.
14.
Zurück zum Zitat Hospital Cost and Utilization Project (HCUP), Nationwide Inpatient Database under the auspices of the Agency for Healthcare Research and Quality (AHRQ). ICD-9 CM Principal Diagnosis Code for HSCT. Hospital Cost and Utilization Project (HCUP), Nationwide Inpatient Database under the auspices of the Agency for Healthcare Research and Quality (AHRQ). ICD-9 CM Principal Diagnosis Code for HSCT.
15.
Zurück zum Zitat Centers for Medicare and Medicaid Services, Hospital Accounting Records, April 28, 2010. Centers for Medicare and Medicaid Services, Hospital Accounting Records, April 28, 2010.
17.
Zurück zum Zitat Kuehn BM. State, federal efforts under way to identify children with “Bubble Boy Syndrome”. JAMA. 2010;304(16):1771–3.CrossRefPubMed Kuehn BM. State, federal efforts under way to identify children with “Bubble Boy Syndrome”. JAMA. 2010;304(16):1771–3.CrossRefPubMed
20.
Zurück zum Zitat Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of hemopoietic stem cells for immunodeficiencies; report of the European experience 1986–1999. Lancet. 2003;361(9357):553–60.CrossRefPubMed Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of hemopoietic stem cells for immunodeficiencies; report of the European experience 1986–1999. Lancet. 2003;361(9357):553–60.CrossRefPubMed
21.
Zurück zum Zitat Hassan A, Booth C, Brightwell A, et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood. 2012;120(17):3615–24.CrossRefPubMed Hassan A, Booth C, Brightwell A, et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood. 2012;120(17):3615–24.CrossRefPubMed
22.
Zurück zum Zitat Modell V, Gee B, Lewis DB, Orange JS, Roifman CM, Routes JM, Sorensen RU, Notarangelo LD, Modell F. Global study of primary immunodeficiency diseases (PI)—diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011;51:61–70.CrossRefPubMed Modell V, Gee B, Lewis DB, Orange JS, Roifman CM, Routes JM, Sorensen RU, Notarangelo LD, Modell F. Global study of primary immunodeficiency diseases (PI)—diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res. 2011;51:61–70.CrossRefPubMed
Metadaten
Titel
An analysis and decision tool to measure cost benefit of newborn screening for severe combined immunodeficiency (SCID) and related T-cell lymphopenia
verfasst von
Vicki Modell
Megan Knaus
Fred Modell
Publikationsdatum
01.10.2014
Verlag
Springer US
Erschienen in
Immunologic Research / Ausgabe 1/2014
Print ISSN: 0257-277X
Elektronische ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-014-8485-4

Weitere Artikel der Ausgabe 1/2014

Immunologic Research 1/2014 Zur Ausgabe

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.